AstraZeneca's global biologics research and development arm MedImmune and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), has entered into a collaboration. The aim is to establish a joint laboratory in Cambridge, UK. The new laboratory will focus on the discoverAlready a subscriber Login You have read all your free articles,…